CLIA Guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA is extending to April 14, 1993 the comment period for a draft guidance document for manufacturers of in vitro diagnostic devices and biologics, according to a notice in the March 5 Federal Register. The draft guidance, released Jan. 12, describes when and how to obtain complexity categorizations and clearance of quality control instructions for tests under the Clinical Laboratory Improvement Amendments of 1988 ("The Gray Sheet" Jan. 18, p. 3). The comment period was originally set to expire March 15.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.